U.S. markets closed
  • S&P Futures

    4,537.25
    -4.50 (-0.10%)
     
  • Dow Futures

    35,509.00
    +29.00 (+0.08%)
     
  • Nasdaq Futures

    15,405.75
    -73.00 (-0.47%)
     
  • Russell 2000 Futures

    2,299.60
    +5.50 (+0.24%)
     
  • Crude Oil

    82.73
    +0.23 (+0.28%)
     
  • Gold

    1,785.90
    +4.00 (+0.22%)
     
  • Silver

    24.25
    +0.08 (+0.33%)
     
  • EUR/USD

    1.1633
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.6760
    +0.0400 (+2.44%)
     
  • Vix

    15.01
    -0.48 (-3.10%)
     
  • GBP/USD

    1.3802
    +0.0007 (+0.05%)
     
  • USD/JPY

    114.1650
    +0.1770 (+0.16%)
     
  • BTC-USD

    62,639.49
    -2,349.71 (-3.62%)
     
  • CMC Crypto 200

    1,490.44
    -44.21 (-2.88%)
     
  • FTSE 100

    7,190.30
    -32.80 (-0.45%)
     
  • Nikkei 225

    28,977.43
    +268.85 (+0.94%)
     

Long-acting injection boosts hopes for GSK's HIV business

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LONDON, Aug 15 (Reuters) - A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business.

GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial.

The result is a boost for GSK's goal of developing two-drug HIV treatments that are easier to tolerate than conventional triple-drug therapies. If follows recent positive data from combining two oral drugs.

GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that currently dominates the HIV market. (Reporting by Ben Hirschler; editing by David Evans)